Subsidiary's Paid-in Capital Increase Finalized
진원생명과학
011000
Signal Score
Historical Avg Return (5d)
+0.38%
Data Coverage
100%n=2330
Risk-adjusted indicator based on 2330 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Capital Increase Amount: 2,979,600,000 KRW (for debt repayment)
- • Subsidiary's Total Assets: 9,906,154,157 KRW
- • Subsidiary's Assets vs. Parent's Consolidated Assets: 8.31%
- • Original Debt Converted: 2,000,000 USD
AI Analysis Summary
GeneOne Life Science, Inc. announced an amendment regarding the paid-in capital increase of its 100% owned overseas subsidiary, Dong-il Interlining Co., Ltd. The capital increase, totaling 2,979,600,000 KRW (equivalent to 2,000,000 USD), was finalized on June 12, 2026, through a debt-to-equity conversion for debt repayment. The subsidiary's assets represent 8.31% of the parent company's consolidated assets. This is a technical amendment to reflect the final payment date and does not introduce new financial figures, thus having a neutral impact.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.